Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.54 |
| ▸ | IDH1 | O75874 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 8/20 | 0.50 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.49 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13777368 | 0.88 | AR (0.56) | SLC22A12IDH1ARTAS2R14ABCG2 | |
| SCHEMBL4594699 | 0.85 | AR (0.56) | IDH1ARGAAMAPTPGR | |
| SCHEMBL6692058 | 0.80 | UTS2R (0.51) | UTS2RGAAMAPT | |
| SCHEMBL6695679 | 0.79 | UTS2R (0.51) | UTS2RPRKCQPRKCDGAAMAPT | |
| SCHEMBL14685064 | 0.78 | SLC22A12 (0.50) | SLC22A12IDH1ARTAS2R14 | |
| SCHEMBL3289311 | 0.78 | AR (0.52) | SLC22A12IDH1ARTAS2R14PGR | |
| SCHEMBL3059987 | 0.78 | SLC22A12 (0.50) | SLC22A12IDH1ARTAS2R14 | |
| SCHEMBL18974782 | 0.78 | SLC22A12 (0.53) | SLC22A12IDH1ARTAS2R14 | |
| SCHEMBL3288072 | 0.78 | SLC22A12 (0.50) | SLC22A12IDH1ARTAS2R14 | |
| SCHEMBL3413737 | 0.78 | TAS2R14 (0.52) | SLC22A12ARTAS2R14ABCG2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194536-A1 | Cyanoarylamines | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| EP-1871379-A2 | CYANOARYLAMINES | Smithkline Beecham Corporation (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006113552-A2 | CYANOARYLAMINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194536-A1 | Cyanoarylamines | EDNRA, CYP19A1, HSD17B11 | SLC22A12 1221/4885IDH1 28/4885AR 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.